I cannot give you one headline for 2026 mass tort litigation without leaving out half the story. Depo-Provera lawyers reached an agreement in principle that could resolve a substantial number of meningioma claims. New federal proceedings were created for Dupixent, Boston Scientific spinal cord stimulators, Roblox child exploitation, Lyft passenger assaults, Cartiva implants, ByHeart infant formula, and GLP-1 vision loss cases.
There has been plenty of bad news, too. The Supreme Court handed Monsanto a serious preemption victory in the Roundup litigation. That ruling makes Bayer’s proposed settlement more attractive to some plaintiffs, even though many believe the proposed payments are too low. The first Paragard bellwether ended in a defense verdict. AFFF personal injury plaintiffs are still waiting for their first trial. Several older dockets look enormous on paper because settlement administration is slow work and cases remain in the federal count while releases, liens, dismissals, and payments are processed.
Here is where things stand for the rest of 2026. I have grouped the cases by what injured people actually need to know: which federal proceedings are moving, which new MDLs deserve attention, and which investigations remain too young for dependable predictions. Where a docket has reached settlement administration, I say that. Where I do not have a confident view yet, I say that, too.
Lawsuit Update Center

